Merck's $4.2B bintrafusp alfa nabs a 3rd strike. Is the GSK-partnered cancer hopeful out? Pfizer, BioNTech score FDA's first full COVID-19 vaccine nod, quickly triggering stricter mandates Pharmacies gearing up to administer COVID-19 booster shots Who's getting the most out of their R&D engine? Pharma's top 11, ranked Abbott destroyed millions of COVID test cards when demand plummeted. Now, it's scrambling to ramp back up Google says health projects will continue even as it unwinds dedicated health division Bristol Myers Squibb nabs priority review tag for $3.15B arthritis drug Orencia to prevent transplant rejection Nordic Capital, Insight Partners take Inovalon private in $7.3B acquisition Cardinal Health lands back-to-back FDA Class I recalls for catheter kits, prefilled syringes Bright Health planning to expand into 42 new markets in 2022 COVID-19 tracker: Pfizer, BioNTech nod quickly spurs stricter mandates; FDA warns against ivermectin to treat COVID Featured Story | By Annalee Armstrong Merck KGaA’s biliary cancer hopeful bintrafusp alfa—the immunotherapy at the heart of a $4.2 billion deal with GlaxoSmithKline—has nabbed its third strike. The German pharmaceutical company announced Monday that a phase 2 clinical trial of bintrafusp alfa has been discontinued as the therapy is unlikely to improve overall survival. read more |
| |
|---|
|
| | Webinar: Removing Antibody Drug Discovery's DNA Bottleneck Tuesday, September 14 | 2pm ET / 11am PT GPCRs have proven to be one of the most challenging targets for antibody drug development. In this webinar, we describe the use of next-generation DNA synthesis tools to overcome the DNA bottleneck in antibody-based GPCR drug discovery. Learn More. |
Top Stories By Noah Higgins-Dunn The U.S. FDA awarded Pfizer and its German partner BioNTech its first full approval for a COVID-19 vaccine, a historic decision that could spark a wave of new vaccine mandates among businesses and universities awaiting the agency's final nod. read more By Paige Minemyer Major pharmacy chains are gearing up to administer COVID-19 booster shots, following the Biden administration's OK last week. read more By Fraiser Kansteiner Drugmakers have myriad tools in their arsenal when looking to grow sales, but it's new drug approvals that reign supreme and ultimately prove the worth of a company's development engine. See how 11 of the world's top drugmakers are faring. read more By Conor Hale While facing sharp declines in public demand for rapid COVID-19 screening over the spring and first half of this summer, Abbott directed its workers to shred millions of paper testing cards that it felt had no chance of selling, according to a report by The New York Times. read more By Heather Landi Google says it is ramping up its investments in health-focused initiatives even as it dissolves its single health division. One industry analyst says the move to shutter the dedicated health division signals the end of a unified healthcare strategy at Google. So what's next for the tech giant's healthcare operations? read more By Fraiser Kansteiner Orencia, which made $3.15B in arthritis last year, is bound for a Dec. 23 decision date and if it passes muster with the FDA, would be cleared for patients ages six and up receiving hematopoietic stem cell transplants from unrelated donors. read more By Dave Muoio The health data software provider's acquisition is expected to close in late 2021 or early 2022 and will net shareholders $41 per share in cash. read more By Andrea Park Cardinal Health is facing two back-to-back product recalls, each of which was characterized this month as Class I, the FDA’s most serious classification, indicating a heightened risk of serious injury or death. read more By Paige Minemyer The insurer said it will be the first plan added to Covered California, the state's exchange, in six years. read more By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner The FDA awarded its first full approval for a COVID-19 vaccine to Pfizer and its partner BioNTech. Meanwhile, regulators are warning against the use of ivermectin tablets, an anti-parasite medicine commonly used in livestock, as a coronavirus med. Plus more. read more |
